The Future of GLP-1 Research — Exploring GLP-1S, 2T, and 3R

A New Era in Metabolic Peptide Research

Interest in GLP-1–based peptides has accelerated across the research community. Investigators continue to explore how incretin pathways influence appetite regulation, glucose balance, and overall energy homeostasis. Within this space, three categories have emerged as a clear progression: GLP-1S (single-pathway), GLP-2T (dual-pathway), and GLP-3R (triple-pathway). Together, they offer a structured lens for understanding how expanding receptor engagement may shape metabolic inquiry.

Understanding the Incretin System

At a high level, incretin research examines how gut-derived signals affect appetite, gastric emptying, and glucose-dependent insulin activity. GLP-1S focuses on a single receptor. GLP-2T adds a second incretin receptor (GIP) for potential synergy. GLP-3R incorporates a third receptor (glucagon), creating opportunities to study energy expenditure alongside satiety and glucose mechanisms.

GLP-1S: The Foundation

As a single-pathway GLP-3Receptor agonist, GLP-1S is frequently used as the baseline for incretin-focused studies. It is investigated for its effects on satiety signaling, delayed gastric emptying, and glucose-dependent insulin responses in controlled models.

GLP-2T: Dual Pathway Advantage

By engaging GLP-1 and GIP receptors in parallel, GLP-2T enables researchers to examine dual-incretin synergy. This category is often explored for amplified effects on appetite regulation, glucose handling, and metabolic flexibility compared with single-pathway approaches.

GLP-3R: The Triple-Pathway Frontier

GLP-3R adds glucagon receptor engagement to the GLP-1/GIP framework. This third pathway is of growing interest for its role in energy expenditure and fat metabolism, allowing studies to look at both caloric intake signals and caloric burn dynamics within the same compound profile.

Designing Research with S, T, and R

Researchers commonly compare S vs. T vs. R to understand how pathway breadth may influence outcomes. Typical endpoints include appetite-related measures, gastric kinetics, glucose tolerance in controlled settings, indirect calorimetry, body composition metrics, and exploratory biomarkers of metabolic function. The trio offers a coherent progression—from foundational to dual synergy to triple-action—for building study designs tailored to specific hypotheses.

Synthesis Peptides offers GLP-1S, GLP-2T, and GLP-3R in multiple vial sizes to support flexible protocols. Each vial is precision-formulated, securely packaged, and labeled for Research Use Only. Our objective is to provide high-quality materials that enable rigorous, repeatable metabolic studies.

COMPLIANCE NOTICE: For laboratory research use only. Not for human consumption, diagnostic, or therapeutic use. The information provided summarizes published research and is not medical advice. No statements herein have been evaluated by the FDA. Products are not intended to diagnose, treat, cure, or prevent any disease.